Page 127 | Certara

Blog

Maximizing Oligonucleotide Therapeutic Development: How They Work

This is the first of three blog posts discussing best practices for developing oligonucleotides. Interest…

CertaraMay 7, 2021

On-Demand Webinar

The Wizard of Oligos: There’s no place like having a successful drug development program!

Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range…

CertaraApril 30, 2021

On-Demand Webinar

The Promises and Pitfalls of Gene Therapy for Rare Diseases

The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have…

CertaraApril 29, 2021

Fact Sheet

Regulatory Writing

Expert Writing. Faster Approvals. Read our Regulatory Writing Factsheet

CertaraApril 28, 2021

Fact Sheet

Anonymization and Redaction

CertaraApril 28, 2021

Fact Sheet

Transparency and Disclosure

Certara delivers expert clinical trial transparency and disclosure services, ensuring compliant global submissions and clear,…

CertaraApril 28, 2021

Fact Sheet

Regulatory Consulting and Regulatory Affairs

CertaraApril 28, 2021

Video

Certara (CERT) – Accelerating Medicines with Biosimulation

As seen on CNBC** Certara is the global leader in biosimulation, a powerful and proven…

CertaraApril 27, 2021

Blog

Planning a Health Canada PRCI Compliant Submission

How to set yourself up for a successful Health Canada PRCI submission

CertaraApril 26, 2021

On-Demand Webinar

Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…

CertaraApril 21, 2021

Maximizing Oligonucleotide Therapeutic Development: How They Work

The Wizard of Oligos: There’s no place like having a successful drug development program!

The Promises and Pitfalls of Gene Therapy for Rare Diseases

Regulatory Writing

Anonymization and Redaction

Transparency and Disclosure

Regulatory Consulting and Regulatory Affairs

Certara (CERT) – Accelerating Medicines with Biosimulation

Planning a Health Canada PRCI Compliant Submission

Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations

Newsletter sign up

Quick links

Solutions

Contact